SCHEMBL2038649

SCHEMBL2038649

COc1cc(NCc2ccc(F)cc2O)cc(Br)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.41
CASP6 P55212 7/20 0.41
MAOB P27338 3/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
MEN1 O00255 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
KMT2A Q03164 3/20 0.39
POLB P06746 1/20 0.39
PLEC Q15149 1/20 0.39
AR P10275 2/20 0.39
USP2 O75604 2/20 0.39
GAA P10253 2/20 0.39
ALOX15 P16050 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ALOX12 P18054 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2042919 0.91 MEN1 (0.41) HDAC3HDAC1HDAC2HDAC6MEN1
SCHEMBL2041507 0.87 KMT2A (0.42) MAOBMEN1ALDH1A1MAPTKMT2A
SCHEMBL2044273 0.84 NOX4 (0.49) MEN1ALDH1A1MAPTKMT2AGAA
SCHEMBL2038643 0.84 MAP2K4 (0.43) MAP2K4CASP6MAOBMEN1ALDH1A1
SCHEMBL2040736 0.81 L3MBTL1 (0.43) MAP2K4CASP6HDAC3HDAC1HDAC2
SCHEMBL2043091 0.80 MAPT (0.47) MEN1ALDH1A1MAPTKMT2APLEC
SCHEMBL2038957 0.78 MEN1 (0.42) MEN1MAPTKMT2AGAAALOX15
SCHEMBL2040730 0.78 PDE2A (0.39) MEN1ALDH1A1MAPTKMT2APLEC
SCHEMBL2041882 0.76 CA12 (0.46) MEN1ALDH1A1MAPTKMT2AAR
SCHEMBL2039704 0.75 KMT2A (0.43) MEN1ALDH1A1MAPTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US claimed
EP-2516400-B1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2017-03-22 EP claimed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US claimed
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US disclosed
EP-2516400-B1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2017-03-22 EP disclosed
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF COLLETTE PATRICE LUCIEN MAURICE (FR) 2016-03-10 US disclosed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US disclosed
EP-2516400-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077046-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA MAP2K4 2865/4885CASP6 2039/4885MAOB 326/4885
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA MAP2K4 2865/4885CASP6 2039/4885MAOB 326/4885
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof TYR, MITF, CUTA MAP2K4 2865/4885CASP6 2039/4885MAOB 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.